How should methotrexate be dosed, administered, and monitored for chronic non‑infectious uveitis (intermediate, posterior, or pan‑uveitis) in an adult without liver disease, renal insufficiency, pregnancy, or severe immunodeficiency?

Methotrexate for Chronic Non-Infectious Uveitis

Methotrexate is an effective steroid-sparing immunosuppressive agent for chronic non-infectious uveitis (intermediate, posterior, or panuveitis) in adults, with a Grade B recommendation based on evidence demonstrating inflammation control, steroid-sparing ability, and maintenance of visual acuity 1.

Treatment Approach

When to Use Methotrexate

Methotrexate should be considered as first-line steroid-sparing therapy when:

• Corticosteroids alone fail to control inflammation
• Prolonged corticosteroid use (>3 months) is anticipated
• Corticosteroid-related side effects become problematic
• Prednisone doses >10 mg/day are required to maintain control

For posterior uveitis and panuveitis specifically, methotrexate demonstrates superior efficacy compared to mycophenolate mofetil, with treatment success rates of 74.4% versus 55.3% 2. However, for intermediate uveitis, mycophenolate may perform better (63.6% vs 33.3% success with methotrexate) 2.

Dosing and Administration

Standard dosing: 25 mg orally once weekly 2, 3

• Oral administration is preferred for low-dose therapy as absorption is rapid and effective serum levels are achieved 4
• Start at full dose (25 mg weekly) rather than titrating up
• If intolerable side effects occur, dose reduction does not significantly compromise treatment outcomes—74% of patients on reduced doses achieved treatment success versus 58% on maximum doses 5

Expected Timeline for Response

• Sustained inflammation control: Achieved in 38.6-55.6% of patients within 6 months 6
• Corticosteroid-sparing success (prednisone ≤10 mg/day with sustained inflammation control): Achieved in 20.7-46.1% within 6 months, increasing to 58.4% by 12 months 6
• Many months may be required for full therapeutic benefit—do not abandon therapy prematurely if partial response is evident

Monitoring Requirements

Baseline assessment:

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel including liver function tests (AST, ALT, albumin)
• Creatinine clearance (particularly important in elderly patients where serum creatinine may overestimate renal function) 4
• Hepatitis B and C screening
• Pregnancy test in women of childbearing potential

Ongoing monitoring:

• CBC and liver function tests every 4-8 weeks initially, then every 8-12 weeks once stable
• Monitor for signs of bone marrow suppression (leukopenia, thrombocytopenia, anemia)
• Watch for elevated transaminases—the most common non-serious laboratory adverse event, occurring in 13% of patients 1

Critical Safety Considerations

Absolute contraindications:

• Pregnancy (Category X) 4
• Breastfeeding 4
• Severe immunodeficiency
• Significant hepatic impairment or active liver disease
• Severe renal insufficiency

Common pitfalls to avoid:

• Do NOT use preserved formulations for intrathecal or high-dose therapy (contains benzyl alcohol) 4
• Methotrexate causes embryotoxicity and fetal defects—ensure reliable contraception in women of childbearing age 4
• In elderly patients, use creatinine clearance rather than serum creatinine alone to assess renal function, as age-related decline increases adverse event risk 4
• Folate supplementation may reduce certain toxicities in chronic use 4

When Methotrexate Fails

Discontinuation rates and reasons:

• 42% of patients discontinue within 1 year 6
• 13% due to ineffectiveness 6
• 16% due to side effects (typically reversible with dose reduction or discontinuation) 6
• 18% require discontinuation for adverse reactions overall 7

If methotrexate fails:

• Consider combination therapy with mycophenolate mofetil (24.1% of patients require this as first revision) 8
• Escalate to biologic therapy, particularly adalimumab (Grade A recommendation) for non-anterior uveitis 1
• Infliximab is also supported (Grade B/C recommendation), especially for Behçet's disease 1

Comparative Effectiveness

Methotrexate versus other antimetabolites:

• No significant difference in uveitis control between methotrexate, mycophenolate mofetil, and azathioprine in comparative studies 1
• However, azathioprine has higher rates of side effects, laboratory complications, and treatment discontinuation compared to methotrexate and mycophenolate 1
• Methotrexate shows a 22% absolute difference in treatment success favoring it over mycophenolate (69% vs 47%), though this did not reach statistical significance 3

Treatment Success Metrics

Define success as achieving ALL of the following at 5-6 months:

1. ≤0.5+ anterior chamber cells, ≤0.5+ vitreous cells, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions in both eyes
2. Prednisone ≤10 mg/day and ≤2 drops of prednisolone acetate 1% daily
3. No treatment failure due to safety or tolerability issues 2, 3

Overall outcomes with methotrexate:

• 76.2% achieve control of inflammation 7
• 56% achieve steroid-sparing effect 7
• 90% maintain or improve visual acuity 7
• Serious adverse reactions occur in only 8.1% of patients with no long-term morbidity or mortality 7

Special Populations

Pregnancy: Methotrexate is absolutely contraindicated—switch to cyclosporine, azathioprine, or certolizumab pegol if immunosuppression is required 9

Elderly patients: Require closer monitoring for bone marrow suppression, thrombocytopenia, and pneumonitis, which increase with age 4. Use accurate renal function assessment (creatinine clearance) rather than serum creatinine alone.